CCMH
BPMC

Cornerstone Capital Management Holdings’s Blueprint Medicines BPMC Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$625K Sell
8,300
-8,700
-51% -$612K ﹤0.01% 978
2017
Q3 		$1.18M Buy
+17,000
New +$908K 0.01% 893

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Cornerstone Capital Management Holdings's BPMC Position: Q4 2017 in Review

Cornerstone Capital Management Holdings reduced its Blueprint Medicines (BPMC) stake by 51% in Q4 2017, selling an estimated $612K and leaving 8,300 shares worth $625K. The position accounts for ﹤0.01% of the portfolio, ranked #978.

Cornerstone Capital Management Holdings first reported a position in BPMC in Q3 2017 and has held it in 2 quarters since. The position peaked at $1.18M in Q3 2017. 170 funds tracked by Wall St. Rank hold BPMC as of Q4 2017.

  • Cornerstone Capital Management Holdings held 8,300 shares of Blueprint Medicines worth $625K as of Q4 2017.
  • Cornerstone Capital Management Holdings sold 8,700 Blueprint Medicines shares in Q4 2017, an estimated $612K.
  • Blueprint Medicines made up ﹤0.01% of Cornerstone Capital Management Holdings's portfolio in Q4 2017, its #978 holding.
  • Cornerstone Capital Management Holdings first reported a position in Blueprint Medicines in Q3 2017 and has held it in 2 quarters since.
  • Cornerstone Capital Management Holdings's Blueprint Medicines position peaked at $1.18M in Q3 2017.
  • 170 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.